Literature DB >> 16738195

Pulmonary function testing in idiopathic interstitial pneumonias.

Fernando J Martinez1, Kevin Flaherty.   

Abstract

Diffuse parenchymal lung diseases are a group of disorders that involve the space between the epithelial and endothelial basement membranes and are generally segregated into four major categories. These include the idiopathic interstitial pneumonias, which are further categorized into seven clinical/radiologic/pathologic subsets. These disorders generally share a common pattern of physiologic abnormality characterized by a restrictive ventilatory defect and reduced diffusing capacity (DLCO). Pulmonary function testing is often used and recommended in their assessment and management. The potential clinical application of physiologic testing includes to aid in diagnosis, although its value in differential diagnosis is limited. Pulmonary function testing also aids in establishing disease severity and in defining prognosis. In nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis, severely decreased DLCO has proven valuable in this regard. Similarly, exertional desaturation to less than 88% at baseline testing and a decrease in FVC (greater than 10%) over the course of short-term follow-up identify patients at particular risk of mortality. Finally, physiologic testing, especially spirometry and DLCO, have demonstrated value in monitoring response to therapy and identifying disease progression.

Entities:  

Mesh:

Year:  2006        PMID: 16738195      PMCID: PMC2658684          DOI: 10.1513/pats.200602-022TK

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  77 in total

1.  Clinical features of three fatal cases of non-specific interstitial pneumonia.

Authors:  J Fujita; I Yamadori; S Bandoh; K Mizobuchi; I Suemitsu; Y Nakamura; Y Ohtsuki; J Takahara
Journal:  Intern Med       Date:  2000-05       Impact factor: 1.271

Review 2.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

3.  Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1.

Authors:  M Brantly; N A Avila; V Shotelersuk; C Lucero; M Huizing; W A Gahl
Journal:  Chest       Date:  2000-01       Impact factor: 9.410

4.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

5.  Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.

Authors:  D S Kim; J H Park; B K Park; J S Lee; A G Nicholson; T Colby
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

6.  Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation.

Authors:  N Mogulkoc; M H Brutsche; P W Bishop; S M Greaves; A W Horrocks; J J Egan
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

7.  High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

8.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

9.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

10.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.

Authors:  T E King; M I Schwarz; K Brown; J A Tooze; T V Colby; J A Waldron; A Flint; W Thurlbeck; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

View more
  35 in total

1.  Influence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.

Authors:  Sean P McGee; Hongmei Zhang; Wilfried Karmaus; Tara Sabo-Attwood
Journal:  Int J Mol Epidemiol Genet       Date:  2014-05-29

2.  T2 mapping of CT remodelling patterns in interstitial lung disease.

Authors:  Maria T A Buzan; Monika Eichinger; Michael Kreuter; Hans-Ulrich Kauczor; Felix J Herth; Arne Warth; Carmen Monica Pop; Claus Peter Heussel; Julien Dinkel
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

Review 3.  Classification and natural history of the idiopathic interstitial pneumonias.

Authors:  Dong Soon Kim; Harold R Collard; Talmadge E King
Journal:  Proc Am Thorac Soc       Date:  2006-06

4.  Clinical expert panel on monitoring potential lung toxicity of inhaled oligonucleotides: consensus points and recommendations.

Authors:  Eric W Alton; Homer A Boushey; Holger Garn; Francis H Green; Michael Hodges; Richard J Martin; Robert D Murdoch; Harald Renz; Stephen B Shrewsbury; Rosanne Seguin; Graham Johnson; Joel D Parry; Jeff Tepper; Paolo Renzi; Joy Cavagnaro; Nicolay Ferrari
Journal:  Nucleic Acid Ther       Date:  2012-07-18       Impact factor: 5.486

5.  Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis.

Authors:  Barbaros Selnur Erdal; Elliott D Crouser; Vedat Yildiz; Mark A King; Andrew T Patterson; Michael V Knopp; Bradley D Clymer
Journal:  Chest       Date:  2012-12       Impact factor: 9.410

6.  Assessment of interstitial lung disease among black rheumatoid arthritis patients.

Authors:  Isabel M McFarlane; Su Yien Zhaz; Manjeet S Bhamra; Aaliya Burza; Srinivas Kolla; Milena Rodriguez Alvarez; Kristaq Koci; Nicholas Taklalsingh; Joshy Pathiparampil; Latoya Freeman; Ian Kaplan; Naureen Kabani; David J Ozeri; Elsie Watler; Mosab Frefer; Vytas Vaitkus; Keron Matthew; Fray Arroyo-Mercado; Helen Lyo; Tomasz Zrodlowski; Aleksander Feoktistov; Randolph Sanchez; Cristina Sorrento; Faisal Soliman; Felix Reyes Valdez; Veena Dronamraju; Michael Trevisonno; Christon Grant; Guerrier Clerger; Khabbab Amin; Makeda Dawkins; Jason Green; Jane Moon; Samir Fahmy; Stephen Anthony Waite
Journal:  Clin Rheumatol       Date:  2019-08-30       Impact factor: 2.980

7.  Assessment of Interstitial Lung Disease Using Lung Ultrasound Surface Wave Elastography: A Novel Technique With Clinicoradiologic Correlates.

Authors:  Ryan Clay; Brian J Bartholmai; Boran Zhou; Ronald Karwoski; Tobias Peikert; Thomas Osborn; Srinivasan Rajagopalan; Sanjay Kalra; Xiaoming Zhang
Journal:  J Thorac Imaging       Date:  2019-09       Impact factor: 3.000

8.  Perfusion- and pattern-based quantitative CT indexes using contrast-enhanced dual-energy computed tomography in diffuse interstitial lung disease: relationships with physiologic impairment and prediction of prognosis.

Authors:  Jung Won Moon; Jang Pyo Bae; Ho Yun Lee; Namkug Kim; Man Pyo Chung; Hye Yun Park; Yongjun Chang; Joon Beom Seo; Kyung Soo Lee
Journal:  Eur Radiol       Date:  2015-08-09       Impact factor: 5.315

Review 9.  Genetics and early detection in idiopathic pulmonary fibrosis.

Authors:  Rachel K Putman; Ivan O Rosas; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 10.  Personalized medicine: applying 'omics' to lung fibrosis.

Authors:  Jose D Herazo-Maya; Naftali Kaminski
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.